entity

Ph

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Ph: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2Connections

30Hypotheses

7Analyses

2Outgoing

0Incoming

20Experiments

9Debates

No AI portrait yet

Wiki Pages (20)

Knowledge base pages for this entity

Lithium for PSP/CBS — Phase 2 Trial

clinical · 4474 words

→

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

clinical · 4279 words

→

Outgoing (2)

Target	Relation	Type	Str
HNRNPA2B1	modulates	protein	0.85
HNRNPA2B1 solubility	regulates	phenotype	0.80

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl	0.964	neuroscience	Circuit-level neural dynamics in neurode
p38α Inhibitor and PRMT1 Activator Combination to Restore Ph	0.879	neurodegeneration	What is the therapeutic window between i
APOE-Dependent Autophagy Restoration	0.877	neurodegeneration	Survival Analysis of AD Patient Cohorts:
eIF2α Phosphorylation Imbalance Creates Integrated Stress Re	0.866	ALS	-
Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated	0.865	molecular neurobiology	View

Glymphatic-Mediated Tau Clearance Dysfunction	0.865	neuroscience	Proteomics Differential Expression in AD
Circadian Glymphatic Entrainment via Targeted Orexin Recepto	0.860	neurodegeneration	Perivascular spaces and glymphatic clear
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.858	ALS	-
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translati	0.856	neurodegeneration	How do pathological stress granules tran
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protectio	0.844	neurodegeneration	Lipid raft composition changes in synapt
Sequential Iron Chelation (Deferoxamine) and GPX4 Restoratio	0.838	neurodegeneration	View
Closed-loop transcranial focused ultrasound to restore hippo	0.827	Alzheimer's disease	Circuit-level neural dynamics in neurode
SIRT1 Activation Couples Mitochondrial Biogenesis to Ferropt	0.824	neurodegeneration	View
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.822	neurodegeneration	What are the mechanisms by which gut mic
HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43	0.820	neurodegeneration	What is the therapeutic window between i
Neutrophil Extracellular Trap (NET) Inhibition	0.806	-	Blood-brain barrier tight junction disru
CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind	0.801	neuroimmunology	TREM2 in Alzheimer's Disease: Mechanisms
pH-Sensitive Bispecific Antibody Targeting Transferrin Recep	0.800	neurodegeneration	Blood-brain barrier antibody transport m
VCP-Mediated Autophagy Enhancement	0.787	neurodegeneration	Tau propagation mechanisms and therapeut
Closed-loop tACS targeting entorhinal cortex layer II SST in	0.784	Alzheimer's disease	Circuit-level neural dynamics in neurode
LAMP2A Liquid-Liquid Phase Separation Defects in Dopaminergi	0.783	neurodegeneration	-
Sleep-Dependent Glymphatic Clearance Expands the Therapeutic	0.780	neurodegeneration	What is the therapeutic window between t
PINK1/Parkin–TREM2 Axis: Convergent Mitophagy Failure Unifie	0.780	neurodegeneration	-
Alpha-gamma cross-frequency coupling enhancement to restore	0.775	Alzheimer's disease	Circuit-level neural dynamics in neurode
Biphasic Ketogenic Intervention Protocol	0.773	metabolic neuroscience	What determines the optimal timing and d
TBK1-OPTN-NDP52 Phospho-Cascade Coordinates Multi-Organelle	0.772	neurodegeneration	How do different organelle-specific auto
Enhancing Microglial Phagocytosis of Extracellular Tau via T	0.771	neuroscience	Trans-synaptic tau spreading and propaga
Circadian Clock-Autophagy Synchronization	0.763	neurodegeneration	Sleep disruption as cause and consequenc
Night-phase orexin receptor antagonism rescues AD by restori	0.758	neurodegeneration	Orexin-A manipulation in AD cognition an
eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote	0.000	ALS	-

Mentioning Analyses (7)

Scientific analyses that reference this entity

How does parthenolide specifically modulate ADORA2A signaling to produce antidep

neuropharmacology | 2026-04-25 | 4 hypotheses Top: 0.659

What causes IBA1 low/negative microglia in liver disease and how does this affec

neuroinflammation | 2026-04-07 | 7 hypotheses Top: 0.710

What determines the specificity of RNA-protein interactions that drive distinct

neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.712

What molecular mechanisms drive microglial senescence and the transition to dyst

neurodegeneration | 2026-04-06 | 7 hypotheses Top: 0.818

How do pathological stress granules transition from reversible to persistent in

neurodegeneration | 2026-04-06 | 7 hypotheses Top: 0.856

Experiments (20)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
MAPK pathway inhibition by QTJD through butyrate mechanism	exploratory	Mycoplasma pneumoniae pneumoni	0.900	0.00	Mouse macrophages	proposed	N/A
iPSC-NPC effects on astrocytes in vitro ICH model	exploratory	intracerebral hemorrhage	0.900	0.00	in vitro ICH cell culture mode	completed	N/A
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
Differential GWAS of schizophrenia vs PTSD	exploratory	schizophrenia, post-traumatic	0.900	0.00	human patients - European ance	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
Creation and validation of 3xAD-ChAT-Cre mouse model	validation	Alzheimer's disease	0.900	0.00	3xAD-ChAT-Cre transgenic mice	proposed	N/A
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co	clinical	Alzheimer's Disease	0.900	0.50	aortic endothelial cells	proposed	$6,550,000
AMPK knockdown validation experiment	exploratory	intracerebral hemorrhage	0.880	0.00	astrocyte cell culture	proposed	N/A
P2RY12-MTOR pathway interaction in VSMCs	exploratory	atherosclerosis	0.850	0.00	cultured VSMCs	proposed	N/A
iPSC-NPC transplantation in ICH animal model	validation	intracerebral hemorrhage	0.850	0.00	animal ICH model	proposed	N/A
GTEx brain tissue expression analysis of MAPT/CRHR1 locus	exploratory	schizophrenia, post-traumatic	0.850	0.00	human brain tissue samples fro	proposed	N/A
PERK Inhibitor GSK2606414 + GADD34 Mimetic Sephin1 Rescues eIF2alpha S	in_vitro	ALS / FTD	0.830	0.85	iPSC-derived motor neurons fro	proposed	$67,000
nSMase2 Inhibitor DPTIP Rescues Synaptic Density in APPswe/PS1deltaE9	in_vivo	Alzheimer's disease	0.803	0.74	APPswe/PS1dE9 bigenic mice, 6-	proposed	$62,000
Microtubule domain analysis in adult axons	exploratory		0.800	0.00	adult rodent axons	proposed	N/A
Tau depletion effects on microtubule domains in adult axons	exploratory		0.800	0.00	adult rodent neurons	proposed	N/A
s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$260,000
Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial	clinical	Neurodegeneration	0.400	0.50	human	proposed	$3,900,000
DLB Cognitive Fluctuation Mechanism Experiment	clinical	Neurodegeneration	0.400	0.50	human	proposed	$6,550,000
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868]	Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X	Pharmacol Rep	2025	1
Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662]	Dashti HS, Daghlas I, Lane JM, Huang Y,	Nat Commun	2021	1
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813]	Sun Y, Tisdale RK, Kilduff TS	Front Neurol Neurosci	2021	1
Sleep drives metabolite clearance from the adult brain. [PMID:24136970]	Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th	Science	2013	1
Replating Induces mTOR-Dependent Rescue of Protein Synthesis in Charcot-Marie-To [PMID:41876253]	Koenig J, McGuire A, Homedan Y, Alberhas	eNeuro	2026	0
S-equol promotes ferroptosis in triple negative breast cancer by coordinating NC [PMID:41925800]	Ni F, Huang Z, Cui Y, Huang P, Xue Z, Hu	Molecular and cellular biochem	2026	0
Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR a [PMID:41445190]	Li J, Li J, Chen K	Mol Ther	2026	0
Senecavirus a VP2 protein orchestrates PRDX1 degradation through dual autophagy [PMID:41479169]	Li Z, Yang X, Mao J, Zeng P, Qi Y et al.	Autophagy	2026	0
Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protei [PMID:41529091]	Liu Y, Sun Y, Song TY, Ni SY, Pu YS et a	Cancer Res	2026	0
Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, [PMID:41651180]	Yang FG, Yang H, Han SW, Wang JT, Gao W	Ageing Res Rev	2026	0
mTOR signaling pathway in primary Sjögren's syndrome: Pathogenesis and potential [PMID:41789635]	Huo R, Yang Y, Wei C, Yang Y, Meng D et	Int J Mol Med	2026	0
Microcystin-LR-induced phosphorylation imbalance and organelle stress: An integr [PMID:41846138]	Teng Z, Shahzad A, Xu Z, Xia J, Zhang J	J Hazard Mater	2026	0
Copper deficiency impairs oligodendrocyte maturation and social behavior via mit [PMID:41920999]	Usui N, Doi M, Berto S, Matsuoka K, Ishi	Sci Adv	2026	0
Crosstalk between inflammation and autophagy in CeD organoids. [PMID:41933042]	Bellomo C, Furone F, Auricchio R, D'Anie	Sci Rep	2026	0
Targeting the AKT/mTOR axis: pectolinarigenin induces autophagy and apoptosis in [PMID:41924135]	Fang Y, Bai J, Bo S, Cui X, Song H, Guo	Frontiers in pharmacology	2026	0
Targeting the GSK-3β/mTOR axis: a novel pharmacological strategy for preeclampsi [PMID:41922823]	Alshaikh ABA, Al-Kuraishy HM, Abdelaziz	Naunyn-Schmiedeberg's archives	2026	0
Platelet proteomic signatures of amyloid β-positive mild cognitive impairment an [PMID:41904574]	Cho YE, Kim A, Lee HM, Oh JW, Son SJ, Ro	Molecular brain	2026	0
Mapping the Brain's Glymphatic System. [PMID:41751308]	Voumvourakis K, Thomaidis NS, Tsiodras S	Biomedicines	2026	0
Targeting of the PI3K/AKT/mTOR signaling pathway in the neurovascular interface [PMID:41865874]	Alameen AAM, Al-Kuraishy HM, Al-Gareeb A	Microvascular research	2026	0
Neuroinflammation, Autophagy, and Neurodegeneration: Mechanisms and Therapeutic [PMID:41918200]	["Khanal P", "Balmik A"]	CNS & neurological disorders d	2026	0

Debates (9)

Multi-agent debates referencing this entity

Debate: Liquid-to-Solid Transition Pathology Reveals Granule Weak Points

closed · Rounds: 4 · Score: 0.58 · 2026-04-27

Debate: TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysre

closed · Rounds: 4 · Score: 0.46 · 2026-04-27

How does parthenolide specifically modulate ADORA2A signaling to produce antidep

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

The study establishes G3BP1's role as a tunable switch for stress granule assemb

closed · Rounds: 4 · Score: 0.69 · 2026-04-22

While single-cell sequencing reveals microglial heterogeneity across regions, ag

closed · Rounds: 4 · Score: 0.73 · 2026-04-22

The study shows stress granules are dynamic and reversible assemblies, but in ne

closed · Rounds: 4 · Score: 0.84 · 2026-04-22

The abstract identifies dystrophic microglia as senescent cells in aged brains b

closed · Rounds: 4 · Score: 0.79 · 2026-04-22

While the study identifies G3BP1 as a central node triggering phase separation,

closed · Rounds: 4 · Score: 0.76 · 2026-04-21

The abstract describes IBA1 low/negative microglia in individuals with liver dis

closed · Rounds: 4 · Score: 0.76 · 2026-04-21

Related Research

Hypotheses and analyses mentioning Ph in their description or question text

Glymphatic-Mediated Tau Clearance Dysfunction

Score: 0.865 · neuroscience · 2026-04-07

## Mechanistic Overview Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within

Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation

Score: 0.860 · neurodegeneration · 2026-04-02

## Mechanistic Overview Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation starts from the claim t

H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State

Score: 0.856 · neurodegeneration · 2026-04-22

## Mechanistic Overview H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State starts from the claim that

Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegenerati

Score: 0.844 · neurodegeneration · 2026-04-07

## Mechanistic Overview Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration starts from t

Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Pre

Score: 0.838 · neurodegeneration · 2026-04-17

## Mechanistic Overview Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-A

Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscilla

Score: 0.827 · Alzheimer's disease · 2026-04-16

## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymph

SIRT1 Activation Couples Mitochondrial Biogenesis to Ferroptosis Suppression via

Score: 0.824 · neurodegeneration · 2026-04-17

## Mechanistic Overview SIRT1 Activation Couples Mitochondrial Biogenesis to Ferroptosis Suppression via PGC1alpha-Depen

Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates

Score: 0.822 · neurodegeneration · 2026-04-05

## Mechanistic Overview Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-

HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase

Score: 0.820 · neurodegeneration · 2026-04-13

## Mechanistic Overview HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase Separation start

Neutrophil Extracellular Trap (NET) Inhibition

Score: 0.806 · unknown disease · 2026-04-16

## Mechanistic Overview Neutrophil Extracellular Trap (NET) Inhibition starts from the claim that modulating PADI4 withi

CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification

Score: 0.801 · neuroimmunology · 2026-04-15

## Mechanistic Overview CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification starts from the cl

pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery

Score: 0.800 · neurodegeneration · 2026-04-22

## Mechanistic Overview pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery starts from the

VCP-Mediated Autophagy Enhancement

Score: 0.787 · neurodegeneration · 2026-04-16

## Mechanistic Overview VCP-Mediated Autophagy Enhancement starts from the claim that modulating VCP within the disease

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa

Score: 0.784 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophag

Ph

Understanding Entity Pages

Wiki Pages (20)

Lithium for PSP/CBS — Phase 2 Trial

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)

Idorsia Pharmaceuticals Ltd.

E2814 — Phase 2 for 4R-Tauopathy

FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear Palsy

Hypera Pharma

KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD Agitation

Aurobindo Pharma Ltd.

Mitsubishi Tanabe Pharma Corporation

CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD

Microglial Phagocytosis in Neurodegeneration

Lupin Pharmaceuticals

PP2A Tau Phosphatase Pathway

LY03020 - Luye Pharma Phase 1 Trial

Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)

Basilea Pharmaceutica AG

Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Disease

Polyneuron Pharmaceuticals AG

Outgoing (2)

Incoming (0)

Targeting Hypotheses (30)

Mentioning Analyses (7)

How does parthenolide specifically modulate ADORA2A signaling to produce antidep

What causes IBA1 low/negative microglia in liver disease and how does this affec

What determines the specificity of RNA-protein interactions that drive distinct

What molecular mechanisms drive microglial senescence and the transition to dyst

How do pathological stress granules transition from reversible to persistent in

How do regional, age, and sex-dependent differences in microglial populations af

How do disease-associated mutations in G3BP1 or its binding partners alter stres

Experiments (20)

Related Papers (20)

Debates (9)

Debate: Liquid-to-Solid Transition Pathology Reveals Granule Weak Points

Debate: TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysre

How does parthenolide specifically modulate ADORA2A signaling to produce antidep

The study establishes G3BP1's role as a tunable switch for stress granule assemb

While single-cell sequencing reveals microglial heterogeneity across regions, ag

The study shows stress granules are dynamic and reversible assemblies, but in ne

The abstract identifies dystrophic microglia as senescent cells in aged brains b

While the study identifies G3BP1 as a central node triggering phase separation,

The abstract describes IBA1 low/negative microglia in individuals with liver dis

Related Research

Glymphatic-Mediated Tau Clearance Dysfunction

Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation

H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State

Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegenerati

Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Pre

Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscilla

SIRT1 Activation Couples Mitochondrial Biogenesis to Ferroptosis Suppression via

Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates

HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase

Neutrophil Extracellular Trap (NET) Inhibition

CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification

pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery

VCP-Mediated Autophagy Enhancement

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa